http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-734071-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f5ef0e68a190669a8aea84eb19c83ee
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
filingDate 2015-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_921b0c567f9b26213fac41f79a287813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07170c005e6f3c4c052d8a570fd6c4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad022bd3e488bb5792360bbe3d28cc76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_824b62a738b79ffa76b32dcb4229f4ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef63a57ded23459913fd6fb1999804c1
publicationDate 2018-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-734071-A
titleOfInvention Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
abstract This invention relates to compounds of formula (I), their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
priorityDate 2014-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487901

Total number of triples: 30.